IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+8.94%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$241M
AUM Growth
+$241M
(-0.03%)
Cap. Flow
+$12.8M
Cap. Flow
% of AUM
5.3%
Top 10 Holdings %
Top 10 Hldgs %
40.16%
Holding
106
New
29
Increased
9
Reduced
21
Closed
6
Top Buys
| 1 |
Merck
MRK
|
$10.6M |
| 2 |
BridgeBio Pharma
BBIO
|
$9.86M |
| 3 |
Insmed
INSM
|
$8.27M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$7.32M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$6.6M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$17.5M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$10.2M |
| 3 |
Biohaven
BHVN
|
$5.94M |
| 4 |
Celldex Therapeutics
CLDX
|
$5.81M |
| 5 |
89bio
ETNB
|
$5.78M |
Sector Composition
| 1 | Healthcare | 97.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Health Care Select Sector SPDR Fund
XLV
$33.8B
| $3.56M | 0.81% |
+27,469
| New | +$3.56M |
|
27
Altimmune
ALT
$325M
| $2.86M | 0.65% |
677,300
+403,868
| +148% | +$1.7M |
|
28
BioVie
BIVI
$12.6M
| $2.82M | 0.64% |
+348,556
| New | +$2.82M |
|
29
Ardelyx
ARDX
$1.57B
| $2.77M | 0.63% |
578,825
-800,000
| -58% | -$3.83M |
|
|
DCPH
30
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $2.7M | 0.61% |
174,510
-192,609
| -52% | -$2.98M |
|
31
Kezar Life Sciences
KZR
$28.5M
| $2.63M | 0.6% |
841,596
+211,610
| +34% | +$662K |
|
32
BioXcel Therapeutics
BTAI
$52.7M
| $2.48M | 0.56% |
133,014
-116,986
| -47% | -$2.18M |
|
33
Aclaris Therapeutics
ACRS
$223M
| $2.43M | 0.55% |
+300,163
| New | +$2.43M |
|
34
Ventyx Biosciences
VTYX
$184M
| $2.18M | 0.49% |
+65,000
| New | +$2.18M |
|
35
Esperion Therapeutics
ESPR
$490M
| $2.16M | 0.49% |
1,355,605
-535,542
| -28% | -$852K |
|
36
Jasper Therapeutics
JSPR
$44.2M
| $2.04M | 0.46% |
+1,126,287
| New | +$2.04M |
|
37
Cytokinetics
CYTK
$5.98B
| $1.96M | 0.44% |
+55,666
| New | +$1.96M |
|
38
Akero Therapeutics
AKRO
$3.65B
| $1.91M | 0.43% |
+50,000
| New | +$1.91M |
|
39
Milestone Pharmaceuticals
MIST
$151M
| $1.81M | 0.41% |
460,416
| – | – |
|
40
MacroGenics
MGNX
$121M
| $1.79M | 0.41% |
+250,000
| New | +$1.79M |
|
|
MORF
41
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $1.73M | 0.39% |
+45,873
| New | +$1.73M |
|
42
Corbus Pharmaceuticals
CRBP
$121M
| $1.4M | 0.32% |
192,260
-204,908
| -52% | +$1.3M |
|
43
ARK Genomic Revolution ETF
ARKG
$1.05B
| $1.4M | 0.32% |
46,462
| – | – |
|
|
BLUE
44
DELISTED
bluebird bio
BLUE
| $1.31M | 0.3% |
412,628
-400,000
| -49% | -$1.27M |
|
|
MRTX
45
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.23M | 0.28% |
33,100
-75,000
| -69% | -$2.79M |
|
46
Karyopharm Therapeutics
KPTI
$61.4M
| $1.17M | 0.26% |
+300,000
| New | +$1.17M |
|
47
Sarepta Therapeutics
SRPT
$1.98B
| $1.15M | 0.26% |
8,324
-20,000
| -71% | -$2.76M |
|
|
ICPT
48
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.14M | 0.26% |
85,200
| – | – |
|
49
Acadia Pharmaceuticals
ACAD
$4.34B
| $1.13M | 0.26% |
60,000
-265,000
| -82% | -$4.99M |
|
50
KalVista Pharmaceuticals
KALV
$713M
| $1.1M | 0.25% |
+140,000
| New | +$1.1M |
|